SOUTH SAN FRANCISCO, Calif. (AP) -- Cytokinetics Inc. said Monday it received a $2.9 million grant from the National Institute of Neurological Disorders and Stroke.
The grant is for research and development of CK-2017357, aimed at treating myasthenia gravis, a neuromuscular disorder that involves muscle weakness and fatigue.
CK-2017357 is currently in midstage clinical development.
Shares of Cytokinetics rose 6 cents, or 2.3 percent, to $2.62 in morning trading. The stock has traded between $2.12 and $5.55 over the last 52 weeks.
